0000000000462416

AUTHOR

Tortorella Carla

showing 2 related works from this author

Clinical and MRI measures to identify non-acute MOG-antibody disease in adults

2022

Abstract MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG antibodies is unavailable or shows uncertain results. We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin 4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of patients with MOG-antibody disease in clinical practice. In this cross-sectional retrospective study, data from 16 MAGNIMS centres were i…

aquaporin 4-antibody positive neuromyelitis optica spectrum disorder; differential diagnosis; imaging; multiple sclerosis; myelin oligodendrocyte glycoprotein antibody-associated diseaseaquaporin 4-antibody positive neuromyelitis optica spectrum disordermyelin oligodendrocyte glycoprotein antibody-associated diseasedifferential diagnosisimagingNeurology (clinical)multiple sclerosis
researchProduct

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic mod…

Male0301 basic medicineDimethyl FumarateNeurodegenerativemultiple sclerosis; coronavirus; pneumoniaSeverity of Illness Indexlaw.inventionImmunosuppressive AgentImmunologic Factor0302 clinical medicineNatalizumablawMonoclonalMultiple Sclerosi80 and overLungHumanizedResearch ArticlesAged 80 and overNatalizumabMiddle AgedIntensive care unitHospitalizationSettore MED/26 - NEUROLOGIAIntensive Care UnitsNeurologyMethylprednisoloneNeurologicalPneumonia & InfluenzaInterferonFemaleImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMusc-19 Study GroupMultiple SclerosisAdolescentClinical SciencesIntensive Care UnitClinical NeurologySettore MED/26Antibodies Monoclonal HumanizedAutoimmune DiseaseAntibodiesYoung Adult03 medical and health sciencesClinical ResearchInternal medicineSeverity of illnessmedicineHumansImmunologic FactorsMortalityAdolescent; Adult; Aged; Aged 80 and over; Antibodies Monoclonal Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young AdultAgedNeurology & NeurosurgeryExpanded Disability Status ScaleFingolimod HydrochlorideSARS-CoV-2business.industryMultiple sclerosisNeurosciencesCOVID-19PneumoniaOdds ratiomedicine.diseaseBrain DisordersGood Health and Well Being030104 developmental biologyOcrelizumabInterferonsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct